New approaches in vaccines, such as DNA vaccines, new combination vaccines, new formulations, novel delivery routes, new adjuvants are being explored. In the last three years the cancer vaccine industry has reshaped itself quite considerably. The number of cancer vaccine players has rather decreased than increased, through operational re-prioritizations, M&As and fall outs.

Scope of this report

In-depth competitive landscape assessment of the cancer vaccine market Tumor antigen discovery and technologies surrounding it Thorough review of immunomodulating strategies and adjuvants Thorough review of cancer vaccine delivery and technologies surrounding it Progress analysis of six major cancer vaccine indications, including players, drugs, clinical progress and pitfalls

Research and analysis highlights

Research and development in the cancer vaccine field is dominated by its top 10 players, interestingly not including any of the big pharma companies per se. The recent Gardasil approval and GlaxoSmithKline's acquisition of Corixa will certainly push the industry towards more acquisitions. With this in mind, this report makes an in-depth assessment of competitive landscape, tumor antigen technologies, immunostimulatory strategies, vaccine delivery technologies, and a progress analysis of six major cancer vaccine indications.

Key reasons to read this report

Understand the clinical and strategic challenges to the commercialization of cancer vaccines Assess opportunities and risks for the continued development of cancer vaccines in six major cancer indications. Adopt knowledge from this analysis to drive strategic planning decisions in oncology drug development

1 Executive Summary
2 Cancer Highlights
3 Methodology
4 4.1 List of Boxes
- 4.2 List of Figures
- 4.3 List of Tables
5 Vaccine Strategies: Challenges & Opportunities
6 Competitive Landscape in Cancer Vaccines
- 6.1 Countries & Players: Who are In the Lead?
  - 6.1.1 Top 10 Players Constitute Up to One Third of R&D: Big Pharma Not Included!
  - 6.1.2 Approved Cancer Vaccine Drugs: Performance
- 6.2 Deals & Alliances in Cancer Vaccines
  - 6.2.1 Recent Mergers & Acquisitions in Cancer Vaccines
  - 6.2.2 Deals in Prostate Cancer
  - 6.2.3 Deals in Breast Cancer
  - 6.2.4 Deals in Leukemia & Lymphoma
  - 6.2.5 Drug Delivery Deals in Cancer Vaccines
  - 6.2.6 Adjuvant Deals
7 Tumor Antigens
- 7.1 Tumor Antigens: General Comments
- 7.2 Antigen Discovery
  - 7.2.1 Classical Immunology Approach
  - 7.2.2 The Reverse Immunology Approach
  - 7.2.3 Company Platforms
    - 7.2.3.1 Epitope Identification System - EIS
    - 7.2.3.2 EPIQUEST system
    - 7.2.3.3 MolecularBreeding & MaxyScan
    - 7.2.3.4 ProtEx technology
    - 7.2.3.5 Rapid Identification of Alternative Splicing (RIAS) System
    - 7.2.3.6 SMARTOMICS
- 7.3 Specific Antigen Processing Technologies Increasing Antigen Presentation
8 Immunomodulators & Adjuvants in Cancer Vaccines
- 8.1 Overview
- 8.2 Cytokines
  - 8.2.1 Vaccines in Combination with Interleukin-2
  - 8.2.2 Tumor Necrosis Factor
  - 8.2.3 Interferons
- 8.3 Adjuvants
- 8.4 Other Immunomodulating Strategies
  - 8.4.1 An Immune Response Modifying Protein
  - 8.4.2 Immunostimulatory DNA
  - 8.4.3 Ex Vivo Stimulated Immune Cells
  - 8.4.4 Fusion Protein Gain Potent Immune Response
  - 8.4.5 Macrophage and Natural Killer Cells Activation
  - 8.4.6 Selective Suppression of the Immune System to An Antigen
  - 8.4.7 TAP Technology
9 Cancer Vaccine Delivery
- 9.1 Viral Delivery
  - 9.1.1 Introduction
  - 9.1.2 Viral Constructs Put into Use
    - 9.1.2.1 Replicon-based RNA and DNA vaccines
    - 9.1.2.1.1 The Alphavaccine Platform System - ArV
    - 9.1.2.1.2 MVA-BN
    - 9.1.2.2 Retroviruses
    - 9.1.2.2.1 The SDSV-platform
    - 9.1.2.3 Lentivirus
    - 9.1.2.3.1 LentiPak
    - 9.1.2.3.2 LentiVector/ pEGASUS
    - 9.1.2.4 Adenoviruses
    - 9.1.2.4.1 Failed Adenovirus Delivery Platforms
    - 9.1.2.4.2 GVAX
    - 9.1.2.4.3 TNFerade
    - 9.1.2.4.4 INGN-225
    - 9.1.2.5 Adeno-associated viruses
    - 9.1.2.5.1 Failed AAV Delivery Platforms
    - 9.1.2.5.2 Genzyme Acquires AAV vector Technology
    - 9.1.2.5.3 MediGene's AAV Platform
    - 9.1.2.6 Herpes Simplex Viruses
    - 9.1.2.6.1 DISC-HSV
    - 9.1.2.6.2 ImmunoVEX
    - 9.1.2.7 Poxviruses
    - 9.1.2.7.1 Hi-8 PrimeBoost platform
    - 9.1.2.7.2 PROSTVAC-VF
    - 9.1.2.7.3 Transgene's MVA Platform
    - 9.1.2.7.4 TroVax
    - 9.1.2.8 Other Poxvirus Systems
    - 9.1.2.9 Baculovirus
    - 9.1.2.9.1 Chimeric virus -like particles (CVLPs)
- 9.2 Bacterias
- 9.3 Cell Therapy: Dendritic-cell Based & Cancer-Cell Based Therapies
  - 9.3.1 Introduction
  - 9.3.2 Cell Therapy Strategies
    - 9.3.2.1 Processed Tumor Cells
    - 9.3.2.2 Lysed Tumor Cell Line
    - 9.3.2.3 The Dendritic Cell Strategy that Didn't Work Out
    - 9.3.2.4 HSPs
    - 9.3.2.5 Provenge
    - 9.3.2.6 Dendritophages
    - 9.3.2.7 Cell-targeting Antibodies
    - 9.3.2.8 Increase Dendritic Cell Number
    - 9.3.2.9 DCVax
    - 9.3.2.10 ACTIVATE
- 9.4 Synthetic Delivery Systems & Strategies
  - 9.4.1 Introduction
  - 9.4.2 Biotransport
  - 9.4.3 Biotypevector
  - 9.4.4 DNAVax Gene Delivery System
  - 9.4.5 FusitAb
  - 9.4.6 GeneDrug
  - 9.4.7 Molecular Conjugates
  - 9.4.8 Naked DNA Delivery
  - 9.4.9 PVLP Technology
  - 9.4.10 Sphingosomal Drug Delivery Technology
  - 9.4.11 STEALTH
  - 9.4.12 Failed Liposomal Systems
10 Non-Antibody Based Vaccines in Development: By Major Indications
- 10.1 General Oncology Overview
- 10.2 Progress Analysis - Melanoma
- 10.3 Progress Analysis - Breast Cancer
- 10.4 Progress Analysis - Prostate Cancer
- 10.5 Progress Analysis - Lung Cancer
- 10.6 Progress Analysis - Colorectal Cancer
- 10.7 Progress Analysis - Cervical Cancer
11 Disclaimer
- 11.1 Liability
- 11.2 Completeness
12 Drug Index
13 Company Index
List of Boxes
- Box 1: Mechanisms Which Tumor Cells Use to Evade an Immune Reaction
- Box 2: M-VAX - Business & Market Bakground
- Box 3: Gardasil: Business & Market Background
- Box 4: TNF in Cancer Treatments
List of Figures
- Figure 1: Top 10 Countries in Cancer Vaccine Research
- Figure 2: Top 10 Companies' Clinical Trial Progress in Cancer Vaccine
- Figure 3: 2003-2005 Deals & Alliances in Cancer Vaccine
- Figure 4: Distribution of Cancer Vaccine Trials in Melanoma
- Figure 5: Distribution of Cancer Vaccine Trials in Breast Cancer
- Figure 6: Distribution of Cancer Vaccine Trials in Prostate Cancer
- Figure 7: Distribution of Cancer Vaccine Trials in Lung Cancer
- Figure 8: Distribution of Cancer Vaccine Trials in Colorectal Cancer
- Figure 9: Distribution of Cancer Vaccine Trials in Cervical Cancer
List of Tables
- Table 1: Companies with Cancer Vaccine Drugs on Market
- Table 2: Antigen Classification
- Table 3: Platforms Used to Improve Antigen Presentation
- Table 4: Cancer Vaccines in Clinical Trials in Combination with Interleukin-2
- Table 5: Adjuvants in Cancer Vaccines
- Table 6: Synthetic Delivery Systems Deployed in Cancer in General and Cancer Vaccines in Particular
- Table 7 Top 10 Cancer Indications in Non-Antibody Based Cancer Vaccines
- Table 8: Discountinued Phase I to Phase III Cancer Vaccine Drugs
- Table 9: List of Phase I to Phase III Cancer Vaccines in Development for Melanoma
- Table 10: List of Phase I to Phase III Cancer Vaccines in Development for Breast Cancer
- Table 11: List of Phase I to Phase III Cancer Vaccines in Development for Prostate Cancer
- Table 12: List of Phase I to Phase III Cancer Vaccines in Development for Lung Cancer
- Table 13: List of Phase I to Phase III Cancer Vaccines in Development for Colorectal Cancer
- Table 14: List of Phase I to Phase III Cancer Vaccines in Development for Cervical Cancer

Pharmaceutical Market Research

Competitive Outlook on Non-Antibody Based Cancer Vaccines